In vivo and in vitro study on the mechanism of anti-cervical cancer
effects of Corilagin in mice
Abstract
Corilagin has several pharmacological effects such as anti-tumor,
anti-inflammatory, and cardiovascular disease treatment. Our previous
studies have shown that the Corilagin can significantly inhibit
proliferation of HeLa cells. However, there is no scientific data on the
anti-cervical cancer effect of Corilagin in vivo. It was speculated that
the mechanism of action for the anti-cervical cancer of Corilagin could
be related to PI3K/AKT and MAPK signaling pathways through network
pharmacology. Results of cell assays in the present study showed that
the Corilagin has significant effect on the proliferation, cell cycle
and apoptosis of murine cervical cancer U14 cells in vitro. In addition,
Corilagin can significantly inhibit the growth of U14 tumor-bearing mice
with insignificant toxic effect on liver and kidney of the transplanted
mice. The current study found that Corilagin can delay development of
cervical cancer by boosting anti-tumor immune responses of body. RT-PCR
and Western blotting were applied in the current study to evident that
Corilagin can achieve anti-cervical cancer property by inducing
apoptosis of tumor tissues through both PI3K/AKT and MAPK signaling
pathways. Therefore, this study provided theoretical reference for
research of Corilagin as a bio-resource for development of an
anti-cervical cancer drug and functional food.